Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:DARE NASDAQ:EVOK NASDAQ:LNAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$13.63-1.4%$13.26$8.74▼$22.90$27.94M0.9628,040 shs9,735 shsDAREDare Bioscience$2.03-4.2%$2.10$1.83▼$9.19$27.36M1.14197,690 shs165,727 shsEVOKEvoke Pharma$4.46-1.3%$5.11$1.94▼$12.32$6.96M-0.131,462 shs46,077 shsLNAILunai Bioworks$1.20-1.6%$0.00$1.11▼$21.00$27.82M0.39458,411 shs165,477 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%+0.07%+3.49%+26.44%-21.03%DAREDare Bioscience0.00%-4.25%-4.25%-24.25%-45.58%EVOKEvoke Pharma0.00%-2.83%-14.56%-4.09%-19.06%LNAILunai Bioworks0.00%+6.19%+119,999,900.00%+119,999,900.00%+119,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$13.63-1.4%$13.26$8.74▼$22.90$27.94M0.9628,040 shs9,735 shsDAREDare Bioscience$2.03-4.2%$2.10$1.83▼$9.19$27.36M1.14197,690 shs165,727 shsEVOKEvoke Pharma$4.46-1.3%$5.11$1.94▼$12.32$6.96M-0.131,462 shs46,077 shsLNAILunai Bioworks$1.20-1.6%$0.00$1.11▼$21.00$27.82M0.39458,411 shs165,477 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics0.00%+0.07%+3.49%+26.44%-21.03%DAREDare Bioscience0.00%-4.25%-4.25%-24.25%-45.58%EVOKEvoke Pharma0.00%-2.83%-14.56%-4.09%-19.06%LNAILunai Bioworks0.00%+6.19%+119,999,900.00%+119,999,900.00%+119,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 2.00Hold$32.00134.78% UpsideDAREDare Bioscience 2.33Hold$10.00392.61% UpsideEVOKEvoke Pharma 1.00SellN/AN/ALNAILunai Bioworks 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest EVOK, CVKD, LNAI, and DARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025EVOKEvoke PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LNAILunai BioworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)9/27/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025EVOKEvoke PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/4/2025DAREDare BioscienceMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.00(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/ADAREDare Bioscience$10K2,736.44N/AN/A($0.69) per share-2.94EVOKEvoke Pharma$10.25M0.68N/AN/A$4.74 per share0.94LNAILunai BioworksN/AN/AN/AN/A($1.24) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)DAREDare Bioscience-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%11/13/2025 (Estimated)EVOKEvoke Pharma-$5.35M-$2.56N/A∞N/A-42.07%-99.48%-33.58%11/6/2025 (Estimated)LNAILunai Bioworks-$178.01M-$7.70N/A∞N/AN/A-222.12%-152.88%N/ALatest EVOK, CVKD, LNAI, and DARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025DAREDare Bioscience-$0.33N/AN/AN/A$0.01 millionN/A11/6/2025Q3 2025CVKDCadrenal Therapeutics-$1.55N/AN/AN/AN/AN/A9/29/2025Q4 2025LNAILunai BioworksN/A-$76.00N/A-$7.60N/AN/A8/14/2025Q2 2025DAREDare Bioscience-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million8/14/2025Q2 2025EVOKEvoke Pharma-$0.30-$0.62-$0.32-$0.62$3.80 million$3.75 million8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/ALNAILunai BioworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A3.553.55DAREDare BioscienceN/A0.340.34EVOKEvoke PharmaN/A1.371.32LNAILunai BioworksN/A0.040.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%DAREDare Bioscience6.70%EVOKEvoke PharmaN/ALNAILunai Bioworks71.41%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics26.09%DAREDare Bioscience4.80%EVOKEvoke Pharma6.10%LNAILunai Bioworks0.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableDAREDare Bioscience3013.48 million12.83 millionNot OptionableEVOKEvoke Pharma41.56 million1.46 millionNot OptionableLNAILunai Bioworks2023.18 million23.06 millionN/AEVOK, CVKD, LNAI, and DARE HeadlinesRecent News About These CompaniesLandmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum ProteomicsOctober 16, 2025 | accessnewswire.comALunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 16, 2025 | accessnewswire.comALunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative PipelineOctober 6, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVOK, CVKD, LNAI, and DARE Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$13.63 -0.19 (-1.37%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$14.02 +0.39 (+2.82%) As of 10/17/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Dare Bioscience NASDAQ:DARE$2.03 -0.09 (-4.25%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.02 -0.01 (-0.49%) As of 06:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Evoke Pharma NASDAQ:EVOK$4.46 -0.06 (-1.33%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$4.53 +0.07 (+1.46%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Lunai Bioworks NASDAQ:LNAI$1.20 -0.02 (-1.64%) As of 10/17/2025 04:00 PM EasternEnochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
